Key Takeaways
- Sales headcount is only one component of commercialization cost.
- Right-sizing depends on the market—rare disease and specialty models often look different from broad primary-care launches.
- Hiring too early creates burn; hiring too late creates execution risk.
- Build a capability and sequencing model before locking a budget narrative for the board.
Boards and CEOs frequently ask a version of the same question: what will it cost to commercialize?
The answer begins with a different question: what commercial system does this therapy actually require?
Copying another company’s organizational chart—or estimating cost from sales headcount alone—often produces the wrong investment thesis. See commercial organization strategy.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
